dc.contributor.author |
Papadogeorgakis, H |
en |
dc.contributor.author |
Caroni, C |
en |
dc.contributor.author |
Katsambas, A |
en |
dc.contributor.author |
Pimenta, JM |
en |
dc.contributor.author |
Avdeliodi, C |
en |
dc.contributor.author |
Kotrotsou, T |
en |
dc.contributor.author |
Frangoulis, E |
en |
dc.contributor.author |
Smith, JS |
en |
dc.date.accessioned |
2014-03-01T01:28:34Z |
|
dc.date.available |
2014-03-01T01:28:34Z |
|
dc.date.issued |
2008 |
en |
dc.identifier.issn |
0956-4624 |
en |
dc.identifier.uri |
https://dspace.lib.ntua.gr/xmlui/handle/123456789/18876 |
|
dc.subject |
Greece |
en |
dc.subject |
Herpes simplex virus |
en |
dc.subject |
Risk factors |
en |
dc.subject |
Seroprevalence |
en |
dc.subject.classification |
Immunology |
en |
dc.subject.classification |
Infectious Diseases |
en |
dc.subject.other |
adolescent |
en |
dc.subject.other |
adult |
en |
dc.subject.other |
article |
en |
dc.subject.other |
child |
en |
dc.subject.other |
diagnostic kit |
en |
dc.subject.other |
education |
en |
dc.subject.other |
female |
en |
dc.subject.other |
Greece |
en |
dc.subject.other |
herpes simplex |
en |
dc.subject.other |
Herpes simplex virus 1 |
en |
dc.subject.other |
Herpes simplex virus 2 |
en |
dc.subject.other |
human |
en |
dc.subject.other |
infant |
en |
dc.subject.other |
major clinical study |
en |
dc.subject.other |
male |
en |
dc.subject.other |
newborn |
en |
dc.subject.other |
priority journal |
en |
dc.subject.other |
risk factor |
en |
dc.subject.other |
seroprevalence |
en |
dc.subject.other |
sexual behavior |
en |
dc.subject.other |
socioeconomics |
en |
dc.subject.other |
Adolescent |
en |
dc.subject.other |
Adult |
en |
dc.subject.other |
Child |
en |
dc.subject.other |
Child, Preschool |
en |
dc.subject.other |
Enzyme-Linked Immunosorbent Assay |
en |
dc.subject.other |
Female |
en |
dc.subject.other |
Greece |
en |
dc.subject.other |
Herpes Simplex |
en |
dc.subject.other |
Humans |
en |
dc.subject.other |
Infant |
en |
dc.subject.other |
Infant, Newborn |
en |
dc.subject.other |
Male |
en |
dc.subject.other |
Middle Aged |
en |
dc.subject.other |
Seroepidemiologic Studies |
en |
dc.subject.other |
Simplexvirus |
en |
dc.title |
Herpes simplex virus seroprevalence among children, adolescents and adults in Greece |
en |
heal.type |
journalArticle |
en |
heal.identifier.primary |
10.1258/ijsa.2007.007142 |
en |
heal.identifier.secondary |
http://dx.doi.org/10.1258/ijsa.2007.007142 |
en |
heal.language |
English |
en |
heal.publicationDate |
2008 |
en |
heal.abstract |
The aim was to study the type-specific seroprevalence of Herpes simplex virus (HSV)-1 and HSV-2 infections and the associated risk factors in children, adolescents and adults in Greece. A total of 1867 serum samples from children, adolescents and adults of both genders aged from 0 to 60 years were collected from three large hospital -referral centres in Athens. All sera were tested for type-specific antibodies to HSV-1 and HSV-2 using HerpeSelect IgG ELISA tests (Focus Diagnostics Cypress, Cal, USA). Overall age-adjusted seroprevalence of HSV-1 and HSV-2 was 72.0% and 10.2%, respectively. HSV-1 seropositivity was low in children up to nine years of age, increased sharply in adolescence, and was higher in females than males in each group surveyed. HSV-2 seropositivity was low (0.8%) below 20 years of age and increased to a maximum prevalence of 18.7% in men and 22.7% in women. Multivariate risk factor analyses indicated that HSV-1 seropositivity was associated with socioeconomic indicators (e.g. lower educational level, residency outside greater Athens), whereas HSV-2 was associated with sexual behavioural factors (e.g. being divorced, greater number of lifetime sexual partners). HSV-2 risk factor profiles were similar in women and in men. This first large seroprevalence study in Greece showed a high age-standardized HSV-1 seropositivity after adolescence and a relatively low age-standardized HSV-2 seroprevalence from birth to 60 years of age. Dual seropositivity to HSV-1 and HSV-2 was low (0.6%) in females under 20 years of age, suggesting that the potential use of an HSV-2 prophylactic vaccine in adolescents could reduce the spread of HSV-2 infection. |
en |
heal.publisher |
ROYAL SOC MEDICINE PRESS LTD |
en |
heal.journalName |
International Journal of STD and AIDS |
en |
dc.identifier.doi |
10.1258/ijsa.2007.007142 |
en |
dc.identifier.isi |
ISI:000255834200013 |
en |
dc.identifier.volume |
19 |
en |
dc.identifier.issue |
4 |
en |
dc.identifier.spage |
272 |
en |
dc.identifier.epage |
278 |
en |